: iStockAnalyst.com Symbols Feed

Invest In HealthCare!

Tue, 01 Dec 2009 16:52:08 GMT

In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single digit pace in the 2nd year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs which pay virtually no interest at all, and long term bonds which pay a little bit more but leave you at the mercy of inflation. Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer (PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Automated Data Processing (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 out of 5 were healthcare companies.[More...]

BioMed News Bytes: AstraZeneca, Delcath, Unilife

Thu, 19 Nov 2009 16:48:58 GMT

On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. This submission is based on the results of a comprehensive program, including data from PLATO (A Study of Platelet Inhibition and Patient Outcomes), the Phase 3 head-to-head trial comparing ticagrelor plus aspirin with clopidogrel (Plavix) plus aspirin. Ticagrelor is the first reversibly binding oral P2Y12 adenosine[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

Dr. Reddy's Laboratories (RDY) Impressive On Both Fundamental And Technical Basis

Mon, 09 Nov 2009 17:00:18 GMT

While I've traded Dr. Reddy's Laboratories (RDY) in the past, I have not touched it in the past few years; however as we await for the new Market Vectors Indian Small Cap fund to launch I was poking my nose around Indian stocks this weekend since the Indian market has corrected quite a bit (and rebounded from oversold levels last week). So this name came back onto my radar in the limited universe of Indian ADRs. (full list of Indian stocks available at TickerSpy)[More...]

Is Bad News Good Again?

Mon, 09 Nov 2009 13:29:08 GMT

There are times in the market when the action make little sense. For example, most investors probably expected the market to decline when the Labor Dept. reported that the Unemployment Rate hit the highest level since 1983. However, we just might be ent[More...]

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Thu, 22 Oct 2009 16:22:43 GMT

With the healthcare debate still raging in Washington, this should shock you… Healthcare mergers and acquisition (M&A) activity is at an all-time high.[More...]

How To Find The Best Potential Profit Plays In The Resurgent M&A And IPO Markets

Tue, 29 Sep 2009 13:52:15 GMT

When Xerox Corp. (NYSE: XRX) yesterday (Monday) unveiled plans to pay $6.4 billion for outsourcing specialist Affiliated Computer Services Inc. (NYSE: ACS), it was just one of four major financing deals with an aggregate value of more than $14 billion announced on the day.[More...]

Market Closing: Nasdaq Leads Decliners; Oil at 2-Month Low

Thu, 24 Sep 2009 20:25:00 GMT

Stocks end lower after disappointing housing data sapped early market strength. The tech-concentrated Nasdaq closes down 1%, as does the S&P 500. The DJIA ends with a slimmer 0.5% decline. Oil hit a two-month low at $65.89 a barrel, also dragging on stocks.[More...]

Which Pharma Pipelines Rank Best?

Thu, 17 Sep 2009 13:42:30 GMT

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.[More...]

Post Market Summary: Wall Street Ends Lower On Recovery Fears, E-Trade (NASDAQ: ETFC) Rallies

Mon, 31 Aug 2009 21:46:00 GMT

US stocks finished lower on Monday after a sharp slide in Chinese stocks reignited fears over the pace of the global recovery.[More...]

Astral Heights - Targacept snares big licensing deal

Fri, 04 Dec 2009 09:50:00 GMT

Dec. 4--Targacept Inc.'s status as an independent, local company grew firmer yesterday with the stunning news of a potential $1.24 billion licensing agreement with AstraZeneca PLC.
The agreement covers Targacept's research breakthrough on treating depression with its TC-5214 drug compound.
Instead, Targacept's management used the leverage of its breakthrough to draw lucrative offers from the companies, said Don deBethizy, the president and chief executive of Targacept.

: iStockAnalyst.com Symbols Feed

Invest In HealthCare!

BioMed News Bytes: AstraZeneca, Delcath, Unilife

Big Pharma And Biotech - Industry Outlook

Dr. Reddy's Laboratories (RDY) Impressive On Both Fundamental And Technical Basis

Is Bad News Good Again?

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

How To Find The Best Potential Profit Plays In The Resurgent M&A And IPO Markets

Market Closing: Nasdaq Leads Decliners; Oil at 2-Month Low

Which Pharma Pipelines Rank Best?

Post Market Summary: Wall Street Ends Lower On Recovery Fears, E-Trade (NASDAQ: ETFC) Rallies

Astral Heights - Targacept snares big licensing deal

Evening Standard, London, market report column

ANALYSIS: Newton's first law: do not lose money

Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years

Green Business Awards 2009

AstraZeneca Q3 Net Income Up

Earnings Preview: Bristol-Myers 3Q earnings report

Drug makers, CVS slammed for promos

Business Highlights

Dampier Defends Woodford Income Strategy

BlackRock Completes Merger With Barclays Global Investors

BlackRock Completes Merger with Barclays Global Investors

Softscape and Jobfox Deliver New Breakthrough Innovation for E-Recruitment

Phase Forward Reports Third Quarter 2009 Results

Howard Dean to Speak at the 2009 Mid-Atlantic Bio Conference

AstraZeneca: Third Quarter and Nine Months Results 2009

POZEN Reports Third Quarter 2009 Results

Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter

Merck Announces Third-Quarter 2009 Financial Results

Cubist Pharmaceuticals 3rd Quarter Total Net Revenues Up 28%